Group 1 - The stock price of Oupankangshi on July 30 was 18.12 yuan, a decrease of 0.08 yuan, representing a decline of 0.44% from the previous trading day [1] - The trading volume on that day was 258,927 hands, with a total transaction amount of 472 million yuan [1] - As of July 18, 2025, the total number of shareholders for Oupankangshi was 62,918 [1] Group 2 - The company's main business involves the research, development, production, and sales of ophthalmic medical devices [1] - Key products include orthokeratology lenses and rigid gas permeable contact lenses [1] - On July 30, the net inflow of main funds was 5.5334 million yuan [1]

证券日报网讯欧普康视（300595）7月30日在互动平台回答投资者提问时表示，截至2025年7月18日，公 司股东总人数为62918户。 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [1][40]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 7.84% from July 11 to July 24, 2025, exceeding the CSI 300's performance by approximately 4.13 percentage points [4][14]. - Most sub-sectors within the industry recorded positive returns during the same period, with the medical research outsourcing and raw materials sectors leading with increases of 14.23% and 9.30%, respectively [4][15]. - Approximately 91% of stocks in the industry achieved positive returns, with notable performers including Borui Pharmaceutical, which saw a weekly increase of 78.98% [16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 7.84% from July 11 to July 24, 2025, surpassing the CSI 300 by about 4.13 percentage points [14]. - Most sub-sectors recorded positive returns, particularly medical research outsourcing and raw materials, which increased by 14.23% and 9.30%, respectively [15]. - About 91% of stocks in the industry had positive returns, with Borui Pharmaceutical leading at 78.98% [16]. 2. Industry News - The report highlights the ongoing progress of the 11th batch of national drug procurement, with significant updates provided during a government open day event on July 22, 2025 [4][28]. - The announcement of the 11th batch of national drug procurement included a notification for drug information submission, which was highly anticipated [4][28]. 3. Company Announcements - Yekang Pharmaceutical announced that its subsidiary received FDA approval for clinical trials of YKYY029 injection for hypertension treatment [29]. 4. Industry Outlook - The report maintains an "Overweight" rating for the industry, citing a continuous rise in the pharmaceutical and biotechnology sector driven by positive sentiment towards innovative drugs and improved financing data [30]. - The report suggests focusing on investment opportunities within the innovative drug supply chain and highlights several companies across various segments, including medical devices, pharmaceutical commerce, and innovative drugs [30][32].

Core Viewpoint - The medical device industry experienced a slight decline of 0.02% on July 23, with a total capital inflow of 23.87 million [1] Group 1: Market Performance - A total of 49 stocks in the sector rose, while 71 stocks fell [1] - The top ten decliners included: - JinHao Medical (-6.2%) - WeiSi Medical (-6.18%) - BeiYiKang (-5.91%) - Rejing Biology (-5.1%) - AiPeng Medical (-3.78%) - DiRui Medical (-3.55%) - YingKe Medical (-2.78%) - AiWei Technology (-2.58%) - YiRui Technology (-2.46%) - KangTuo Medical (-2.35%) [1] Group 2: Capital Flow - The net capital outflow for the top decliners included: - JinHao Medical: -15.52 million - WeiSi Medical: -13.50 million - BeiYiKang: -9.36 million - Rejing Biology: -14.75 million - AiPeng Medical: -15.57 million [1] Group 3: Top Gainers - The top gainers in the sector included: - OuPuKangShi (14.13%) - TouJing Life (5.7%) - KangZhong Medical (5.07%) - TianYi Medical (4.97%) - AoTai Biology (3.52%) [1]

Market Overview - As of 10:29 AM today, the Shanghai Composite Index stands at 3592.77 points, above the annual line, with a change of 0.30% [1] - The total trading volume of A-shares today is 857.68 billion yuan [1] Stocks Breaking Annual Line - A total of 27 A-shares have surpassed the annual line today, with notable stocks including: - Opcon Vision (300595) with a deviation rate of 9.58% - Mars (300894) with a deviation rate of 6.80% - Xianju Pharmaceutical (002332) with a deviation rate of 3.03% [1] Deviation Rate Rankings - The following stocks have the highest deviation rates from the annual line: - Opcon Vision: Today's increase of 12.38%, turnover rate of 3.83%, annual line at 16.41 yuan, latest price at 17.98 yuan [1] - Mars: Today's increase of 8.18%, turnover rate of 8.48%, annual line at 13.62 yuan, latest price at 14.55 yuan [1] - Xianju Pharmaceutical: Today's increase of 5.12%, turnover rate of 5.68%, annual line at 10.36 yuan, latest price at 10.67 yuan [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the annual line include: - Beiqi Blue Valley (600733) with a deviation rate of 0.03% - Qianhe Flavor (603027) with a deviation rate of 0.05% - Luyang Energy (002088) with a deviation rate of 0.15% [2]

Core Viewpoint - The medical device sector is experiencing a rally, driven by the active innovation drug concept, with significant gains in stock prices for companies like Opcon Vision, which hit a 20% limit up [1] Group 1: Market Performance - Opcon Vision's stock reached a 20% limit up, indicating strong investor interest and confidence in the company [1] - Other companies in the sector, such as Maipu Medical, saw stock increases of over 10%, reflecting a broader positive trend in the medical device market [1] Group 2: Industry Insights - According to a report from Guotai Junan, domestic equipment monthly bidding data shows a continuous recovery, suggesting improving market conditions [1] - As inventory pressures ease, equipment companies are expected to see a quarter-on-quarter performance recovery in Q3, indicating a potential turnaround in the sector's financial health [1]

证券代码：300595 证券简称：欧普康视 公告编号：2025- 060 欧普康视科技股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会召开期间无否决提案的情况； 2、本次股东大会未出现涉及变更以往股东大会已通过决议的情况。 一、会议召开和出席情况 1、会议召开时间： 现场会议时间：2025 年 7 月 22 日 14:45 网络投票时间：通过深圳证券交易所交易系统网络投票时间为 7 月 22 日 9:15-9:25，9:30-11:30 和 13:00-15:00；深圳证券交易所互联网投票系统投票 时间为 7 月 22 日 9:15 至 15:00。 2、会议召开地点：合肥市高新技术开发区望江西路 4899 号 2 号楼二楼会议 室。 3、会议召开方式：现场投票与网络投票相结合的方式。 4、会议召集人：公司第四届董事会。 5、会议主持人：公司董事长陶悦群先生。 6、本次股东大会召集、召开与表决程序符合《公司法》《上市公司股东会 规则》等法律、行政法规、部门规章、规范性文件和《公司 ...

关于欧普康视科技股份有限公司 2025 年第一次临时股东大会法律意见书 天律意 2025 第 01900 号 天禾律师 股东大会法律意见书 致：欧普康视科技股份有限公司 安徽天禾律师事务所 本法律意见书是天禾律师根据对本次股东大会事实的了解及对我国现行法 律、法规和规范性文件的理解而出具的。 天禾律师同意将本法律意见书作为本次股东大会的法定必备文件予以公告， 并依法对所出具的法律意见书承担责任。 天禾律师根据《证券法》相关规定的要求，按照律师行业公认的业务标准、 道德规范和勤勉尽责精神，对本次股东大会的召集、召开、与会人员资格、表决 程序及其他相关法律问题发表如下意见： 一、关于本次股东大会的召集、召开程序及召集人资格 （一）经验证，根据公司第四届董事会第十六次会议决议，公司于 2025 年 7 月 5 日在巨潮资讯网（http://www.cninfo.com.cn）刊登了《关于召开 2025 年 第一次临时股东大会通知的公告》。 （二）本次股东大会现场会议于 2025 年 7 月 22 日 14:45 在公司会议室召 开，本次股东大会由公司董事会召集，公司董事长陶悦群先生主持。 （三）本次股东大会网络投票 ...

Core Insights - The vision correction industry in China is experiencing rapid growth driven by policy support, market demand, and technological innovation [1][5][22] - The market size is projected to reach 215 billion yuan in 2024, with a year-on-year growth of 11.6% [1][14] - The industry has established a comprehensive treatment system combining surgical and optical correction methods [1][10] Policy Support - The Chinese government has implemented a series of policies to enhance eye health, including the "Comprehensive Prevention and Control of Myopia in Children and Adolescents Implementation Plan" [5][7] - Policies aim to create a management system covering prevention, treatment, and rehabilitation, promoting standardized and high-quality development in the industry [5][22] Market Demand - The number of myopic individuals in China has surpassed 600 million, with a significant increase in myopia rates across all age groups [8][12] - The myopia rate among high school students exceeds 80%, and projections suggest that the rate for the 16-24 age group may reach 94% [8][12] - This growing patient base provides a continuous driving force for the industry's development [1][8] Industry Structure - The vision correction industry has formed a complete industrial chain, with upstream focusing on optical materials and high-end equipment, while midstream includes the production of glasses and surgical devices [10][20] - The downstream market is served by medical institutions, optical centers, and e-commerce platforms, with private eye hospitals contributing over 60% of refractive surgeries [10][12] Competitive Landscape - The industry features a multi-layered competitive structure, with foreign brands dominating high-end markets while domestic brands accelerate their presence [20][21] - Key players include Aier Eye Hospital, Aibo Medical, and Opcon Vision, each with distinct market positions and strategies [21][20] Future Trends - The industry is expected to continue expanding due to policy-driven demand and technological advancements, with a focus on full-cycle management of eye health [22][24] - Innovations such as AI-assisted surgeries and domestic alternatives to imported products are reshaping the competitive landscape [24][25] - The trend towards service accessibility is being driven by private institutions expanding into lower-tier cities and the growth of online sales channels [25][22]

第四届监事会第十七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏 一、监事会会议召开情况 （一）欧普康视科技股份有限公司（以下简称"公司"）第四届监事会第十 七次会议，于 2025 年 7 月 14 日以专人送达、即时通讯等方式发出会议通知。 （二）会议于 2025 年 7 月 18 日以现场形式召开。 证券代码：300595 证券简称：欧普康视 公告编号：2025-058 欧普康视科技股份有限公司 具体内容详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）披露的 《关于部分募投项目结项并将节余募集资金永久补充流动资金及注销募集资金 专户的公告》。 本议案需提交股东大会审议。 三、备查文件 （三）本次会议应参与表决监事 3 人，实际参与表决监事 3 人。 （四）会议由监事会主席孙永建先生主持。 （五）本次会议召开符合《公司法》和《公司章程》的有关规定。 二、监事会会议审议情况 经投票表决，会议审议通过如下决议： 以 3 票赞成，0 票反对，0 票弃权审议通过《关于部分募投项目结项并将节 余募集资金永久补充流动资金及注销募 ...